ABSTRACT
Hepatitis C virus has been found to be associated with B-cell non-Hodgkin lymphomas, mostly marginal zone lymphomas and diffuse large B-cell lymphoma.
Deregulation of signaling pathways involved in normal marginal zone development (NOTCH pathway, NF-κB, and BCR signaling) has been demonstrated in splenic marginal zone lymphoma.
We studied mutations of NOTCH pathway signaling in 46 patients with hepatitis C virus-positive diffuse large B-cell lymphoma and in 64 patients with diffuse large Bcell lymphoma unrelated to HCV. NOTCH2 mutations were detected in 9/46 (20%) hepatitis C virus-positive patients, and NOTCH1 mutations in 2/46 (4%). By contrast, only 1/64 HCV-negative patients had a NOTCH1 or NOTCH2 mutation. The frequency of the NOTCH pathway lesions was significantly higher in hepatitis C viruspositive patients (P=.002). The 5-year overall survival was 27% (95% CI, 5%-56%) for hepatitis C virus-positive diffuse large B-cell lymphoma patients carrying a NOTCH pathway mutation versus 62% (95%CI: 42%-77%) for those without these genetic lesions. By univariate analysis, age >60 years, NOTCH2 mutation, and any mutation of the NOTCH pathway (NOTCH2, NOTCH1, SPEN) were associated with shorter overall survival. Mutation of the NOTCH pathway retained an independent significance (P=.029).
In conclusion, a subset of patients with hepatitis C virus -positive diffuse large B-cell lymphoma displays a molecular signature of splenic marginal zone and has a worse clinical outcome.
INTRODUCTION

Hepatitis C virus (HCV) HCV infection is a risk factor for the development of B-cell
non-Hodgkin lymphomas (B-NHL), either indolent B-NHL such as splenic marginal zone lymphoma (SMZL) or diffuse large B-cell lymphoma (DLBCL) (1, 2) .
Beside epidemiological evidence, the direct relationship between SMZL and HCV infection is also clinically supported by SMZL regression after antiviral treatments (3, 4) .
Unbiased genomic studies have unraveled the typical coding genome of SMZL, which is characterized by mutations of genes involved in the physiological differentiation and homeostasis of marginal zone (MZ) B-cells (5, 6) . Indeed, the commitment and retention of mature B-cells to the MZ compartment requires NOTCH2 signaling activation. Consistently, the NOTCH pathway is affected in ~30-40% of SMZL, including mutations of NOTCH2, the master regulator of MZ B-cell differentiation, in ~25% of cases. In addition to NOTCH2, other modulators or members of the NOTCH pathway are recurrently targeted by genetic lesions in SMZL, including NOTCH1, a paralog of NOTCH2, and SPEN, the main negative regulator of NOTCH signaling in MZ B-cells. NOTCH2 mutations are also recurrent in clonal B-cell lymphocytosis with a MZ phenotype (7), a recently recognized entity (8) that may represent a precursor of MZL.
HCV-positive DLBCL patients display specific presentation with respect to their HCVnegative counterparts, as documented by the preferential involvement of the spleen, and the occasional residual signs of low-grade lymphoma (9) (10) (11) . These clinical and pathologic features suggest that at least a fraction of HCV-positive DLBCL may represents the transformation of a pre-existent, though unrecognized MZL clone.
Though the genetics of DLBCL arising in HCV negative patients has been extensively investigated, few data are currently available about the molecular mechanisms involved in the development of DLBCL in HCV subjects.
In this study we document that: i) NOTCH pathway mutations are a molecular clue associated to ~25% HCV-positive cases among DLBCL; and ii) among HCV-positive DLBCL, the molecular deregulation of NOTCH signaling associates with the coexistence of a low grade component in the diagnostic biopsy and poor outcome.
Overall, these data suggest that at least a fraction of HCV-positive DLBCL may represent the transformed phase of a MZL clone. For comparative purposes, 64 HCV-negative DLBCL were also included in the study.
METHODS
Patients
All of the 64 samples had been obtained at diagnosis from the involved site (lymph nodes or extranodal sites). HCV-positive and HCV-negative cohorts were matched for age.
Mutation analysis
The mutation hotspots of NOTCH1 (exon 34; RefSeq NM_017617. 
RESULTS
Clinico-pathologic features of HCV-positive DLBCL
Clinical and pathologic features of 46 patients with HCV-positive DLBCL are summarized in Table 1 . All patients with the exception of 2 have been treated with CHOP or CHOP-like regimen (in 15 coupled with rituximab).
All cases were HCV-RNA positive and HCV genotype was investigated in 11 patients: 5 had genotype 1b and 6 genotype 2a/2.
Extranodal disease was present in 72% (33/46) of patients and 17 patients had splenic involvement, including 32% (15/46) of patients with primary splenic disease.
Cryoglobulins were detected in 26% (8/31) patients. Clinical features did not differ between NOTCH mutated and NOTCH wild type patients ( Table 2 ).
Among 9 patients with NOTCH2 mutation, 4 had extranodal disease (1 spleen, 1 parotid gland, 1 meninges, salivary gland and liver and one muscle). 
NOTCH pathway mutations are restricted to HCV-positive DLBCL
In order to define whether NOTCH pathway mutations are a genetic event specifically associated to DLBCL of the HCV infected patient, NOTCH2 and NOTCH1 mutations were investigated in a cohort of 64 HCV-negative DLBCL. NOTCH2 was rarely mutated in 1/64 (1.6%) of HCV-negative DLBCL (comparison with HCV-positive cases resulted statistically significant, p = 0.002) while NOTCH1 was never affected (0/64) (comparison with HCV-positive cases, p=0.173, Figure 3 ).
Impact of NOTCH pathway disruption on outcome of HCV-positive DLBCL
After a median follow up of 3.7 years for entire series, the 5-year OS was 53% (95% CI: 37%-67%). In univariate analysis on HCV-positive DLBCL, the only factors negatively affecting OS are age, the nodal disease respect to extranodal disease and the mutation of NOTCH pathway (Table 3) . Precisely, 5-year OS was 27% (95% CI: 5%-56%) for patients carrying NOTCH pathway mutation and 62% (95%CI: 42%-77%) for patients without these mutations (Figure 4) .
In multivariate analysis, adjusting for clinical features significantly associated to OS in univariate analysis, the adverse prognostic impact of NOTCH pathway mutations was confirmed (HR=2.5; 95%CI: 1.0-5.8; p=0.041), while age lost their significance (HR=1.0; 95%CI: 0.9-1.1; p=0.101) and the nodal disease became of borderline significance (HR=2.3; 95%CI: 1.0-5.5; p=0.050). (19) (20) (21) (22) , but less attention has been paid to HCV-positive DLBCL (23). In the available series of HCV-positive DLBCL, it has been noticed a predilection for extranodal presentation, including spleen tissue (9) (10) (11) 24) .
DISCUSSION
Majority of clinical and biological investigations focused on HCV-positive MZL
In the present study we document that: i) NOTCH pathway mutations are a molecular clue associated to ~25% HCV-positive cases among DLBCL; and ii) among HCVpositive DLBCL, the molecular deregulation of NOTCH signalling associates with the coexistence of a low grade component in the diagnostic biopsy and poorer outcome.
A key finding of this study was the identification of alterations on genes of the NOTCH pathway as highly recurrent in HCV-positive DLBCL. In particular NOTCH2, known as a key regulator of MZ development, was the most frequently mutated gene (20%) This frequency is consistent with the prevalence of NOTCH2 mutations documented in SMZL (5, 6, 18, 25, 26) and significantly higher than that observed in HCV-negative DLBCL (this study), and more in general, in unselected DLBCL cohorts (27, 28) (Supplemental table 4 ). All NOTCH2 mutations observed in HCVpositive DLBCL cause disruption of the protein inhibitory PEST domain and are predicted to activate NOTCH signalling (27) .
In the general population most cases of DLBCL arise de novo but about 10% of cases are transformed from low-grade B-cell lymphomas, such as chronic lymphocytic leukemia (29) Overall, these data further support the notion that a subgroup of DLBCL arising in subjects carrying HCV infection represent the transformation of a previous, clinically unrecognized, indolent MZL.
It is notewhorty that NOTCH signaling plays a role in marginal zone B-cell differentiation in the spleen (33) and that a lymphoid neoplasm as splenic marginal zone lymphoma is frequently associated to cryoglobulinemia and HCV infection (34) . 
